Search clinical trials for: MOR103

Total 72 results

MorphoSys AG

Completed

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Multiple Sclerosis

Germany, Poland, United Kingdom
Galapagos NV

Terminated

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis (GECKO)

Atopic Dermatitis

United States
Alan Richardson
Quotient Clinical

Terminated

First in Human Single Ascending Dose Study of MOR107

Safety

United Kingdom
MorphoSys AG

Completed

Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

Bulgaria, Germany, Netherlands, Poland, Ukraine
Galapagos NV

Terminated

A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis

Healthy | Atopic Dermatitis

Spain, Germany, Ukraine, United Kingdom
Galapagos NV
MorphoSys AG

Completed

First in Human of Single and Multiple Doses of MOR106

Healthy | Dermatitis, Atopic

Belgium, Hungary, Moldova, Republic of, Romania
Sorriso Pharmaceuticals, Inc.

Recruiting

A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis

Ulcerative Colitis

Ukraine, Georgia
Wolfson Medical Center
Meditor Pharmaceuticals Ltd.

Unknown

Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients

End Stage Renal Disease | Hypotension | Intra Dialytic Hypotension

Israel
Meditor Pharmaceuticals Ltd.

Withdrawn

Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery Patients

Hypotension | Cardiopulmonary Bypass

United States
I-Mab Biopharma Co. Ltd.

Completed

Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors

Solid Tumor | Metastatic Cancer | Advanced Cancer

United States
MorphoSys AG

Terminated

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

Acute Lymphoblastic Leukemia

United States
MorphoSys AG

Completed

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin Lymphoma

United States, Belgium, Germany, Hungary, Italy, Poland, Spain
Herlev and Gentofte Hospital
University of Copenhagen

Completed

A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma

Basal Cell Carcinoma

Denmark
Cliniques universitaires Saint-Luc- Université...

Recruiting

Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. (HN1901)

Oropharynx Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Larynx Squamous Cell Carcinoma

Belgium
Lene Meldgaard Knudsen
IO Biotech

Terminated

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

Denmark
Amgen Research (Munich) GmbH

Completed

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

Non-Hodgkin's Lymphoma, Relapsed

Germany
Amgen Research (Munich) GmbH

Completed

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

Germany
Lemonex

Recruiting

Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)

COVID-19 Infection | COVID-19 Vaccine Adverse Reaction

Korea, Republic of
HI-Bio

Completed

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (M-PLACE)

Glomerulonephritis, Membranous | antiPLA2R Positive

Spain, Belgium, Australia, Italy, United States, Korea, Republic of, France, Netherlands, Poland
Immune Response BioPharma, Inc.

Unknown

REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study (RAISE)

HIV

United States
Amgen Research (Munich) GmbH

Completed

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States, Germany, Austria, Canada, France, Italy, Netherlands
Amgen Research (Munich) GmbH

Completed

Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

B-ALL

Germany
Amgen Research (Munich) GmbH

Completed

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Germany
Mario Negri Institute for Pharmacological Research
MorphoSys AG

Active, not recruiting

MOR202 for Refractory MN (MONET)

Membranous Nephropathy

Italy
Amgen Research (Munich) GmbH

Completed

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) (BLAST)

B-cell Acute Lymphoblastic Leukemia

Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, United Kingdom
Amgen Research (Munich) GmbH

Completed

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States, United Kingdom, Germany, Spain, France, Italy
HI-Bio

Completed

Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE) (NewPLACE)

Glomerulonephritis | Membranous Nephropathy | antiPLA2R Positive

Taiwan, Korea, Republic of, Greece, Germany, United Kingdom, Georgia, Russian Federation
HI-Bio

Active, not recruiting

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy (IGNAZ)

Immunoglobulin A (IgA) Nephropathy

United Kingdom, Germany, Spain, Serbia, Taiwan, Australia, Japan, Korea, Republic of, Belgium, United States, Bulgaria, Czechia, Georgia, Malaysia, Philippines, Ukraine
Farsad Eskandary
Charite University, Berlin, Germany; University of Alberta; HI-Bio

Completed

Felzartamab in Late Antibody-Mediated Rejection

Antibody-mediated Rejection

Austria, Germany
Aurigene Discovery Technologies Limited

Recruiting

A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics (BHARAT-1)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Non Hodgkin Lymphoma | Solid Tumor, Adult

India
James Rubenstein
Incyte Corporation

Recruiting

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Primary Central Nervous System Lymphoma | CNS Lymphoma | Secondary Central Nervous System Lymphoma

United States
IO Biotech
Merck Sharp & Dohme LLC; Syneos Health

Active, not recruiting

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Metastatic Melanoma | Unresectable Melanoma

Hungary, Spain, United Kingdom, Australia, France, Italy, United States, Denmark, Germany, Israel, Czechia, Belgium, Netherlands, Turkey, Poland, South Africa
Amgen

Completed

Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

China
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
IO Biotech
Merck Sharp & Dohme LLC; Theradex; Almac

Recruiting

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Melanoma | Squamous Cell Carcinoma of Head and Neck

United States, Australia, Denmark, Spain, France, Germany
IO Biotech
Merck Sharp & Dohme LLC; Theradex; Almac; NeoGenomics

Recruiting

IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma Bladder | Lung Cancer Non Small Cell

United States, Spain, United Kingdom
Lars Møller Pedersen
IO Biotech

Completed

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Chronic Lymphocytic Leukemia

Denmark
Memorial Sloan Kettering Cancer Center
IO Biotech

Recruiting

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

Melanoma

United States
Amgen

Terminated

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

United States, France, Italy, Belgium, Canada, Mexico, Germany, Korea, Republic of, United Kingdom, Taiwan, Australia, Spain, Austria, Israel, Czechia, Greece, Russian Federation, Poland, Turkey, Bulgaria, Ireland
MorphoSys AG

Completed

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)

Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, United Kingdom, Austria, Germany, Italy, Poland
The Lymphoma Academic Research Organisation

Recruiting

Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

DLBCL

France, Belgium
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditions

United States
Amgen
Merck Sharp & Dohme LLC

Completed

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) (HARBOUR)

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

United States, Germany, Spain, Australia, Netherlands, France
Inge Marie Svane

Recruiting

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

Metastatic Melanoma

Denmark
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Minimal Residual Disease | Adult Acute Lymphoblastic Leukemia in Complete Remission

United States
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia

United States
Brian Jonas
National Cancer Institute (NCI); Pharmacyclics LLC.

Recruiting

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

Philadelphia Chromosome Positive | Adult B Acute Lymphoblastic Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia

Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | CD19 Positive

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States

Search clinical trials for: MOR103

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations